News
PulseSight Therapeutics has dosed the first subject in the Phase I trial of its first-in-class non-viral vectorised therapy, PST-611.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback